Poster Highlights the Ability of Non-Invasive Vagus Nerve Stimulation (nVNS) to Accelerate Learning of a Second Language ROCKAWAY, N.J. , March 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that data
ROCKAWAY, NJ , March 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Strategy Officer, Joshua Lev , will participate in a fireside chat at the 35th Annual Roth
Record full year 2022 net sales of $ 8.6 million increased 58 % over $ 5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J. , March 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a
ROCKAWAY, N.J. , March 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated March
ROCKAWAY, N.J. , March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2022 , after the close of the market on
ROCKAWAY, N.J. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with Byond Healthcare Pty Ltd. to serve as the exclusive distributor of gammaCore Sapphire TM ,
ROCKAWAY, N.J. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents and intends to issue a third new patent related to
ROCKAWAY, N.J. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology
ROCKAWAY, N.J. , Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-15.
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022 Revenue growth of approximately 57% over full-year 2021 Launched two new brands; TAC-STIM ™ under the Air Force BOOST program and Truvaga ™ wellness product for stress,